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A B S T R A C T
Over the past three decades, we studied 184 individuals with 174 different molecular variants of branched-chain
α-ketoacid dehydrogenase activity, and here delineate essential clinical and biochemical aspects of the maple
syrup urine disease (MSUD) phenotype. We collected data about treatment, survival, hospitalization, metabolic
control, and liver transplantation from patients with classic (i.e., severe; n = 176), intermediate (n = 6) and
intermittent (n = 2) forms of MSUD. A total of 13,589 amino acid profiles were used to analyze leucine tol-
erance, amino acid homeostasis, estimated cerebral amino acid uptake, quantitative responses to anabolic
therapy, and metabolic control after liver transplantation. Standard instruments were used to measure neu-
ropsychiatric outcomes. Despite advances in clinical care, classic MSUD remains a morbid and potentially fatal
disorder. Stringent dietary therapy maintains metabolic variables within acceptable limits but is challenging to
implement, fails to restore appropriate concentration relationships among circulating amino acids, and does not
fully prevent cognitive and psychiatric disabilities. Liver transplantation eliminates the need for a prescription
diet and safeguards patients from life-threatening metabolic crises, but is associated with predictable morbidities
and does not reverse pre-existing neurological sequelae. There is a critical unmet need for safe and effective
disease-modifying therapies for MSUD which can be implemented early in life. The biochemistry and physiology
of MSUD and its response to liver transplantation afford key insights into the design of new therapies based on
gene replacement or editing.
1. Introduction
In 1954, Menkes and colleagues described four siblings who were
born healthy but developed encephalopathy within the first week of life
and died by age three months with cerebral edema and urine odor
“strikingly similar to that of maple syrup” [1]. Branched-chain α-ke-
toacid dehydrogenase (BCKD) deficiency, more commonly known as
maple syrup urine disease (MSUD; MIM 248600), was subsequently
traced to biallelic mutations in one of three genes (BCKDHA, BCKDHB,
DBT) which encode subunits of the multimeric mitochondrial complex
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that decarboxylates α-ketoacid derivatives (BCKAs) of the branched-
chain amino acids (BCAAs): leucine, isoleucine, and valine.
MSUD affects ~1 per 150,000 newborns in outbred populations
[2,3] but is enriched within certain endogamous groups [4,5]. Among
North American Old Order Mennonites, severe (‘classic’) MSUD affects
as many as 1 per 400 births due to a founder variant of BCKDHA
(c.1312T > A, p.Tyr438Asn) which has drifted to a high carrier fre-
quency (~10%) in certain extant demes. The Clinic for Special Children
(CSC) is sited in rural Pennsylvania, a region densely populated with
Mennonites, and since 1989 has drawn an ethnically and genetically
diverse group of MSUD patients from 25 US states and seven countries.
Classic MSUD is among the most volatile and dangerous inherited
metabolic conditions: acute elevations of leucine and α-ketoisocaproic
acid (αKIC) cause metabolic encephalopathy and critical brain edema,
whereas chronic amino acid and neurotransmitter imbalances pose risk
for intellectual disability, executive dysfunction, and psychiatric illness
(Fig. 1) [6]. Dietary therapy is challenging to implement and manage-
ment of each metabolic crisis is precarious and complex [7]. Orthotopic
liver transplantation restores BCAA homeostasis but introduces short-
and long-term health risks [8]. Thus, there remains a pressing need for
better, safer, disease-modifying therapies.
Gene replacement and editing technologies hold promise [9], but a
paucity of natural history and biomarker data can impede the design of
clinical trials for rare disorders [10,11]. The CSC cohort closes this gap,
representing a broad spectrum of MSUD patients followed prospectively
at a single center for three decades. Here, we draw on this experience to
Fig. 1. Pathophysiology of maple syrup urine disease
(A) In patients with MSUD, branched-chain α-ke-
toacids cannot be oxidized (O) by the dehydrogenase
complex (BCKDH) and leucine tolerance (I) reflects
unmeasured (‘insensible’) protein losses and the
balance between endogenous protein synthesis (S)
and degradation (D). Leucine comprises ~10% of
tissue protein (~110 g/kg of body weight) and can
increase rapidly during catabolic states, altering
brain chemistry by competing with nine other amino
acids for entry into the brain via the facilitative
SLC7A5 transporter. Branched-chain amino acid
transaminase (BCAT1) catalyzes the formation of α-
ketoisocaproic acid (αKIC) from leucine and α-ke-
toglutarate (αKG); αKIC enters brain via the mono-
carboxylate transporter (SLC16A1) and is neurotoxic
at high concentrations. (B) Elevated tissue αKIC re-
verses normal flow through BCAT1, depletes tissues
of glutamate (a substrate for glutamine and γ-ami-
nobutyric acid [GABA]), and indirectly drives flux
through glutamate-pyruvate transaminase (GPT;
a.k.a. ALT, SGPT) to form pyruvate from α-ketoglu-
tarate (αKG) and alanine (Ala). In patients with
classic MSUD, these interconversions explain inverse
relationships of leucine to glutamate, glutamine, and
alanine, and likely underlie the depletion of gluta-
mate and elevation of lactate observed in brain tissue
during metabolic encephalopathy (purple asterisk
traces the normal physiologic flow of leucine-derived
nitrogen). (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
K.A. Strauss, et al. Molecular Genetics and Metabolism xxx (xxxx) xxx–xxx
2
describe key elements of the MSUD phenotype and delineate essential
outcome measures for clinical trials.
2. Methods
2.1. Patients and clinical methods
Using CSC clinical databases and Mennonite historical records [12],
we identified 190 individuals with a clinical diagnosis of MSUD. Reli-
able data were available for 184 of them, 175 of whom had molecular
confirmation of MSUD by sequencing of BCKDHA (n = 135), BCKDHB
(n = 26), or DBT (n = 14) in the CSC core laboratory (Table S1). The
study was conducted under Penn-Lancaster General Hospital IRB pro-
tocol 2008–095-CSC. All surviving patients or their parents consented
in writing to participate.
We analyzed a total of 13,589 amino acid profiles collected in
clinical (plasma) or home (dried filter paper blood spots) settings and
comprised of samples from patients with biallelic BCKDHA
c.1312 T > A mutations (n = 12,042), other classic genotype com-
binations (n = 1024), intermediate MSUD (n = 159), or following liver
transplantation (n = 364). Sample timing was intentionally random to
capture the full variation of plasma amino acid values in relation to
feeding, fasting, and illness. Blood amino acid concentrations were
compared to those from a control population of 52 Amish and
Mennonite children not affected by disorders of amino acid or organic
acid metabolism and reported, unless otherwise noted, as the mean
value± one standard deviation (SD).
Half of the amino acid profiles (n = 6784) were collected from a
subgroup of 41 BCKDHA c.1312 T > A homozygotes (~165 samples
per patient) born between 2005 and 2018 who were treated pro-
spectively with a single line of medical foods (Nutricia North America)
enriched with seven amino acids (see below) that compete with BCAAs
for cerebral uptake across the blood-brain barrier via the SLC7A5 (a.k.a.
LAT1) transporter. The formulation intended for infants (Complex
Junior MSD) was found to be safe and well-tolerated in a clinical trial
[13]. Between 12 and 24 months of age, patients were transitioned to a
second formulation (Complex Essential MSD) with a different vitamin
blend and twice the amino acid content. An MSD Amino Acid Blend was
prescribed on a limited basis to some older patients seeking weight
control.
Episodic elevations of leucine were managed at home using a ‘sick-
day’ diet recipe devoid of leucine and high in calories, BCAA-free amino
acids, isoleucine, and valine [7]. Patients hospitalized for metabolic
encephalopathy were treated according to a standard inpatient protocol
(Table 1) using a custom MSUD total parenteral nutrition (TPN) solu-
tion that could be formulated on-demand at Penn Medicine-Lancaster
General Hospital inpatient pharmacy. Continuous intravenous insulin
was used to maintain euglycemia and optimize protein anabolic rates
during hyperalimentation. Intravenous infusions of isoleucine and va-
line (20–120 mg/kg·day each) were used in parallel with TPN to opti-
mize the anabolic rate of leucine utilization. In severely intoxicated
patients, mannitol (10%), hypertonic saline (3%), and furosemide were
administered judiciously to prevent extracellular hypo-osmolality and
mange brain edema [7]. Enteral (or parenteral) leucine was typically
reintroduced when the plasma concentration decreased to<100 μmol/
L.
2.2. Metabolic phenotyping
2.2.1. Dietary leucine tolerance and protein turnover
Leucine tolerance is defined as the weight-adjusted daily leucine
intake that is sufficient for normal growth and maintains plasma leucine
concentration within the normal reference range (mean ± 2SDs). In
persons with classic MSUD, in vivo oxidation and urinary losses of
BCAAs are negligible [14,15]. Thus, leucine tolerance reflects a balance
between unmeasured protein losses (e.g., sloughed skin, hair, and nails)
and the net accretion of body protein, which in turn is linked to growth
rate [16]. During metabolic crises, changes of plasma leucine trace
whole body protein turnover, which can be quantified if one assumes
the human body is 10–12% protein [17], protein is 7–8% leucine by
weight [18,19], and free leucine (molecular weight 131 mg/mmol) is
evenly distributed in total body water (Fig. 1) [20]. In other words,
Table 1
Inpatient management of MSUD metabolic crisis.
Primary Clinical Goals
▪ Decrease plasma leucine concentration by 500–1000 μmol/L per 24 h.
▪ Maintain serum osmolality within the normal range (~285–300 mOsm/kg H2O)
and prevent it from decreasing > 0.20 mOsm/kg H2O per hour (> 5 mOsm/kg
H2O per day)
▪ Maintain serum sodium concentration of 138–145 mEq/L with minimal fluctuation
▪ Monitor for and treat signs of intracranial hypertension and impending brain
herniation
▪ Anticipate and prevent iatrogenic abnormalities associated with high infusions of
fluid, glucose, and insulin (e.g. hyperglycemia, hypoglyemia, hyponatremia,
hypokalemia, hypophosphatemia)
General Measures
▪ Identify and treat precipitating catabolic stressors (e.g., infection, dehydration,
trauma)
▪ Establish euvolemia using isotonic sodium chloride solutions
▪ Establish central venous access
▪ Schedule antipyretics (e.g. acetaminophen, ibuprofen, ketorolaca) to control fever
▪ Administer antiemetics (e.g., ondansetron) to control nausea and vomiting
▪ Limit use of glucocorticoids and vasoactive catecholaminergic agents
▪ Alleviate agitation and physical pain
Metabolic Treatment
▪ Provide 1.5- to 3-times estimated energy expenditure (EER) as dextrose (50–70%)
and lipid (30–50%)b
▪ When central access allows, use 25% dextrose solutions to minimize complications
of hypervolemia
▪ Continuous insulin infusion: 0.02–0.15 units/kg·hour; titrate to maintain blood
glucosec 100–160 mg/dL
▪ Total protein equivalent intake (enteral + parenteral)d: 2.0–3.5 g/kg·day as BCAA-
free amino acids
▪ Isoleucine and valine supplements (enteral + parenteral)e: 20–120 mg/kg·day each;
titrate to plasma concentrations of 400–800 μmol/L
Cerebral Edema
▪ Monitor for signs of intracranial hypertension and impending brain herniation
▪ Administer hypertonic (3%) saline drip: 2–10 mEq/kg·day sodium chloride; titrate
to serum osmolality 285–300 mOsm/kg H2O, serum sodium 138–145 mEq/L, and
serum osmolality change ≤ 0.2 mOsm/kg H2O·hour (≤ 5 mOsm/kg H2O·day)
▪ Treat symptomatic hypo-osmolality or worsening signs of intracranial hypertension
using the following agents alone or in sequence: mannitol 0.5–1 mg/kg·dose;
hypertonic (3%) saline 2–3 mEq/kg·dose; furosemide 0.5–1.0 mg/kg·dose
▪ For obtunded patients with cerebral edema, consider endotracheal intubation for
airway protection and neurosurgical consultation to consider intracranial pressure
monitoring, active CSF drainage, etc.
Laboratory Monitoring
▪ Serum (and/or point-of-care) glucose every 4–6 h
▪ Serum osmolality and electrolytes every 6–12 h
▪ Plasma amino acids, serum phosphorus and magnesium every 12–24 h
▪ Serum lipase, amylase, and transaminases every 24–48 h
a Ketorolac has potent effects on renal blood flow; it is contraindicated in
patients who are dehydrated, known to have kidney disease, or taking other
medications that affect renal perfusion.
b In older children and adults, calorie intakes 3-times EER (i.e., 6000 cal per
day) are sometimes necessary to drive a net shift to protein anabolism and
necessitate central venous access.
c Blood glucose can be measured from serum samples or using reliable point-
of-care methods.
d Parenteral MSUD amino acid solutions are available from only a very
limited number of specialty pharmacies, and often prove difficult to procure in
a timely manner. For patients of any age who can tolerate enteral feeding (even
if intubated), continuous nasogastric delivery of a BCAA-free MSUD formula
(0.7–1.2 kcal/mL; 30–60 mL/h) supplemented with 1% liquid solutions of
isoleucine and valine can be an effective way to meet protein equivalent goals
while providing additional calories in the form of intravenous dextrose and/or
lipid.
e For parenteral administration, isoleucine and valine are each prepared as
separate 1% solutions in normal saline.
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leucine represents ~1% of total and newly accreted body mass.
2.2.2. BCAA homeostasis
The wild type BCKD complex maintains tight stoichiometric re-
lationships among the three BCAAs, such that plasma concentration
ratios (μmol/L:μmol/L) of leucine to isoleucine (Leu/Iso) and valine to
leucine (Val/Leu) remain close to 2.0 in diverse physiological contexts,
including overnight fasting, protein loading, and catabolic illness. In
contrast, these concentration ratios vary across several orders of mag-
nitude in patients with classic MSUD [8].
2.2.3. Alloisoleucine
Alloisoleucine is a chemical derivative of isoleucine and represents
the most sensitive and specific diagnostic marker for all forms of MSUD.
Plasma alloisoleucine is< 5 μmol/L in healthy infants, children, and
adults, and exceeds this value in 94% and 99.9% of samples from pa-
tients with intermediate and classic forms of MSUD, respectively [21].
2.3. Estimation of cerebral amino acid influx
A custom Excel spreadsheet (Microsoft Corporation) was designed
to estimate the transport of BCAAs and seven other amino acids from
blood to brain, as previously described [16]. Briefly, a group of ten
zwitterionic amino acids (glutamine, histidine, isoleucine, leucine,
methionine, phenylalanine, threonine, tryptophan, tyrosine, and va-
line), most of which are essential, compete for entry into the brain via
SLC7A5 [22]. The transporter is saturated under physiological condi-
tions, such that cerebral uptake of each SLC7A5 substrate is influenced
by ambient concentrations of its competitors. Competition is expressed
by an apparent Km, called Kapp (μmol/L), calculated for each amino acid
according to the equation:
= + +K K 1 (C K )
n
napp m
1
i i
(1)
Where Km is the classical Michaelis-Menten affinity constant for the
single amino acid of interest, Ci is the plasma concentration (μmol/L)
for each of n competitors, and Ki is the classical affinity constant of that
competitor (μmol/L). For a given plasma amino acid profile, Kapp values
were determined for each SLC7A5 substrate using published Michaelis-
Menten parameters [22]. The Kapp value was then used to estimate the
brain influx (nmol per minute per gram of brain tissue) of each amino
acid in the competing group, according to the equation:= +Influx (V ) (C)/(K C)max app (2)
Where Vmax and C are the maximal transport velocity (nmol/min·g)
and plasma concentration (μmol/L), respectively, of each amino acid
[23]. Estimated brain influx values were compared to those calculated
from a control population (N = 52) and depicted as standard scores
(i.e., z-scores), where z = [(patient value – control mean)/control
standard deviation]. All cerebral uptake values represent calculated
heuristics and should not be interpreted as direct measurements of
amino acid flux.
2.4. Psychometric testing
Eighty-two classic MSUD patients had IQ testing using the Stanford-
Binet Intelligence Scales, 5th Edition (SB-5) [24], which assesses full-
scale intelligence quotient (FSIQ) as well as subdomains for verbal and
non-verbal IQ, memory, visual-spatial, quantitative, and fluid rea-
soning, and fund of knowledge. The cohort tested was comprised of 30
BCKDHA c.1312 T > A homozygotes born between 1967 and 2004, 21
BCKDHA c.1312 T > A homozygotes born between 2005 and 2018
and treated prospectively with SLC7A5 substrate-enriched medical
foods, and 31 non-Mennonites with classic MSUD. For a subgroup of
31BCKDHA c.1312 T > A homozygotes (DOB 1967–2004 [n = 15];
DOB 2005–2018 [n = 16]), IQ testing was performed on age-matched
control siblings for comparison. Twenty patients (mean 12.0 ± 6.7,
range 3.6–22.4 years) underwent neurocognitive testing before and
≥1 year after liver transplantation.
Diagnoses of depression, anxiety, and panic disorder were guided by
the Structured Clinical Interview for the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV) or its childhood
version. Age-adjusted measures for depression and anxiety were drawn
from the Beck Depression and Anxiety Inventories or subscores of the
Beck Youth Inventories of Emotional and Social Impairment. Scaled
scores for adult and youth versions were reconciled by calculating z-
scores, as previously described [6].
2.5. Statistical methods
All statistical calculations were performed using Prism 8 (https://
www.graphpad.com). For comparisons involving three or more groups,
we used one-way analysis of variance (ANOVA) and the Tukey post-test
to detect pairwise differences among groups (Tukey p < .05). Where
matching was appropriate, intra- and intersubjective neurocognitive
measures were compared using a paired, two-tailed t-test. Associations
between variables were generally tested using simple linear regression
or Spearman's test for correlation (rs). The Pade approximant function
in Prism 8 was used to fit plasma concentration relationships between
leucine and other circulating non-essential amino acids (e.g. alanine,
glutamine, tyrosine). For Kaplan-Meier analyses, death or permanent
ischemic brain injury attributable to cerebral edema were considered
equivalent endpoints. The Mantel-Cox log-rank test was used to detect
differences (χ2) between curves.
3. Results
3.1. Cohorts
The CSC clinical database included 184 MSUD patients (median age
18.2, range 0.1–52.9 years; 51% female) representing 3512 aggregate
patient–years. For the purpose of this study, we divided them into five
groups: (1) Mennonite BCKDHA c.1312 T > A homozygotes born
between 1963 and 1988 (n = 30), prior to CSC's inception; (2) BCKDHA
c.1312 T > A homozygotes born between 1989 and 2018 (n = 89); (3)
non-Mennonites with a classic MSUD phenotype caused by various
biallelic mutations of BCKDHA, BCKDHB, or DBT (n = 57; Table S1);
(4) six patients with residual BCKD activity and an intermediate bio-
chemical phenotype; and (5) two siblings with intermittent MSUD who
were compound heterozygous for DBT c.75_76delAT and c.901C > T.
We did not identify any individuals with PPM1K variants of MSUD [25].
A subgroup of BCKDHA c.1312T > A homozygotes born between 2005
and 2018 were treated on a consistent prospective protocol using
SLC7A5 substrate-enriched medical foods as previously described [13],
and were the source of data about contemporary dietary treatment and
monitoring (Section 3.3).
3.2. Survival, biochemical control, and metabolic crises
Eleven (37%) of 30 Mennonites born with classic MSUD prior to
CSC's inception (i.e. birthdate 1963–1988) died from complications of
metabolic encephalopathy between 36 days and 9.7 years of age
(Fig. 2A). Mortality was lower (χ2 = 37.9, p < .0001) among 145
classic MSUD patients born after 1988: two (1.4%) died from compli-
cations of cerebral edema (ages 9.6 and 15.4 years) and one died of
acute viral myocarditis (2.3 years). Εvent-free survival did not differ
between Mennonite (n = 89) and non-Mennonite (n = 57) patients
born after 1988 (χ2 = 0.51, p = .477).
In patients with classic MSUD on dietary therapy, average plasma
leucine was 282 ± 259 μmol/L (normal reference range
119 ± 38 μmol/L) (Fig. 2B) and showed considerable inter- and
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intraindividual variation (Fig. 2C). Mean BCAA concentrations did not
differ between BCKDHA c.1312T > A homozygotes and those with
other allele combinations. Average plasma leucine was similar in pa-
tients with classic as compared to intermediate MSUD (Fig. 2B, Table 2)
but individuals in the latter group tolerated more intact protein, mon-
itored plasma amino acids less frequently, and required less nutritional
support during metabolic crises. Leucine showed strong inverse
Spearman correlations (p < .0001) to multiple other circulating amino
acids, most notably alanine (rs = −0.61), glutamine (rs = −0.52),
tyrosine (rs = −0.49), and threonine (rs = −0.47) (Fig. 2D).
Acute metabolic intoxication necessitated 296 hospitalizations be-
tween December 1990 and May 2019. Intercurrent infection pre-
cipitated 219 (75%) of these events. Gastroenteritis (44%) was the most
common admitting diagnosis but a diverse array of catabolic stresses
necessitated hospitalization (Table S2). Patients were admitted at a
median age of 5.6 (range birth to 39.8) years with leucine values of
(caption on next page)
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960 ± 509 (20–4812) μmol/L. Plasma leucine decreased 509 ± 243
(146–1446) μmol/L·day in the hospital to reach a median nadir of 86
(25–496) μmol/L within 2 (0.5–7) days (Fig. 2E). The average rate of
endogenous net protein synthesis in response to anabolic therapy was
0.43 ± 0.20 (0.10–1.34) grams/kg·day and did not differ as a function
of age (rs = −0.044, p = .523). Total inpatient stay ranged from 0.5 to
62 days per admission. The overall hospitalization rate decreased 96%
between 1989 and 2015, from 7.0 to just ~0.25 hospital days per pa-
tient per year (p < .0001) (Fig. 2F). We did not utilize hemodialysis to
manage any metabolic crises, although this strategy can effectively
reduce plasma leucine in patients with MSUD [26,27].
3.3. Contemporary dietary management
Among 41 BCKDHA c.1312 T > A homozygotes (DOB 2005–2018)
treated prospectively from birth with SLC7A5 substrate-enriched for-
mulas, 21 (51%) were targeted for umbilical cord molecular testing
based on parental carrier status and diagnosed at an average of 12 h of
life; most remained asymptomatic throughout a safe perinatal transition
at home. Twenty (49%) babies were detected by state newborn
screening. Neonates in this latter group were diagnosed at an average of
5 days of age and in some cases presented symptomatic with high
plasma leucine concentrations (1123–2769 μmol/L); three were hos-
pitalized between 7 and 11 days of age for metabolic encephalopathy.
The remaining 17 (85%) babies diagnosed by newborn screening were
managed successfully at home, provided the child had no or only mild
signs of encephalopathy and could tolerate a sufficient volume of ‘sick-
day’ formula and the parents could commit to assiduous clinical and
amino acid monitoring in the outpatient setting.
Throughout infancy, energy intake from the sum of intact and
BCAA-free liquid sources aligned with values predicted by the doubly-
labeled water method (http://nap.edu/11537). Between 1 and
3.5 years of age, the proportion of calories from unquantified natural
sources came to represent ~30% of energy intake (Fig. 3A). Weight-
adjusted leucine tolerance decreased from 72 ± 13 mg/kg·day in
newborns to 10 ± 2 mg/kg·day in adults (Fig. 3B) and paralleled a
decrement of total weight-adjusted protein equivalent from the sum of
intact and BCAA-free sources, which nevertheless remained 25–50%
Fig. 2. Aggregate MSUD cohort (n = 184, DOB 1963–2018): survival, biochemical control, and metabolic crises (A) Eleven (37%) of 30 Mennonites born with MSUD
between 1963 and 1988 died early in life from complications of metabolic encephalopathy. Mortality was lower among 146 classic MSUD patients born after 1988
and was similar between Mennonites (n = 89) and non-Mennonites (n = 57). (B) Average plasma leucine were 1.5– to 2–times the upper limit of normal in patients
with classic (blue circles, biallelic BCKDHA c.1312 T > Amutations; purple diamonds, other allele combinations) and intermediate (green triangles) forms of MSUD.
(C) There was significant inter- and intraindividual metabolic variability, as depicted by comparing a patient with relatively tight longitudinal control (blue dia-
monds) to one with recurrent metabolic crises (red circles) requiring hospitalizations (red arrowheads, upper frame) (gray shaded area: mean ± 2SD normal
reference range for plasma leucine). (D) Plasma leucine showed strong inverse Spearman correlations (p < .0001) to multiple other circulating amino acids, most
notably alanine (blue circles, rs = −0.61), glutamine (purple triangles, rs = −0.52), and tyrosine (green diamonds, rs = −0.49). (E) Between December 1990 and
May 2019, there were 296 hospitalizations for metabolic intoxication, during which plasma leucine decreased 509 ± 243 μmol/kg·day to reach a median nadir of 86
(25–496) μmol/L within 2 (0.5–7) days. Different symbols-lines represent leucine curves for three hospitalized individuals and represent what clinicians can expect to
observe as rapid (greed diamonds), average (purple squares), and slow (blue circles) rates of metabolic correction in response to anabolic therapy, with extreme rates
for the cohort (146–1446 μmol/kg·day) indicated by gray dashed lines. The net endogenous protein synthetic rate in response to inpatient anabolic therapy averaged
0.43 ± 0.20 (0.10–1.34) g/kg·day and did not vary by age. (F) Prior to the CSC's inception, overall hospitalization rate for BCKDHA c.1312 T > A homozygotes was
7 hospital days/patient·year. Innovations in local monitoring and clinical care led to a steep decline after 1988 to ~0.25 hospital days/patient·year by 2005
(p < .0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
MSUD biomarkers.
Plasma Concentration (μmol/L) Concentration Ratio (mol:mol)
Leucine Isoleucine Valine Alloisoleucineb Leucine/Isoleucine Valine/Leucine
Mean (SD) Range Mean (SD) Range Mean (SD) Range Mean (SD) Range Mean
(SD)
Range Mean
(SD)
Range
Control (n = 51; N = 51)a 119 (38) 62–200 65 (25) 26–121 208 (61) 118–335 nd 1.81
(0.31)
1.15–3.41 1.73
(0.21)
1.13–2.49
Classic MSUD (n = 12,043;
N = 165)
282 (259) 2–3008 240 (190) 5–3141 495 (250) 1–3298 190 (117) 0–746 1.66
(2.24)
0.01–103.70 3.47
(4.54)
0.002–104.90
Intermediate MSUD (n= 158;
N = 6)
324 (469) 12–2201 187 (250) 34–2457 428 (455) 53–5269 52 (58) 0–271 1.87
(0.84)
0.08–5.72 2.00
(1.80)
0.52–14.62
Liver Transplant (n = 241;
N = 61)
187 (62) 79–422 144 (53) 40–363 324 (109) 155–639 4 (8) 0–32 1.33
(0.28)
0.90–4.00 2.05
(0.53)
1.05–5.80
One-way ANOVA P <0.0001 <0.0001 <0.0001 <0.0001 <0.0001c < 0.0001c
Tukey Pairwise Comparisonsd
Control vs. Classic **** **** **** na ns **
Control vs. Intermediate **** *** **** na ns ns
Control vs. Liver Transplant ns * * na ns ns
Classic vs. Intermediate ns ** ** **** ns ****
Classic vs. Liver Transplant **** **** **** **** *** ****
Intermediate vs. Liver
Transplant
**** ns *** *** *** ns
Abbreviations: ANOVA, analysis of variance; n, number of samples analyzed; N, number of patients; na, not applicable; nd, not detected; ns, not significant (p > .05);
SD, standard deviation.
a ‘N’ indicates the number of individuals in each group; ‘n' indicates the number of samples analyzed: e.g. among 165 individuals with Classic MSUD, an average of
73 blood samples per subject yielded 12,043 amino profiles for one-way ANOVA analysis.
b Our laboratory began quantitative alloisolecuine concentrations in recent years. Thus, sample numbers are smaller for Classic (n = 633), intermediate
(n = 156), and transplanted (n = 121) MSUD patients.
c BCAA concentration ratios were log10 transformed for statistical comparisons.
d *p < .05; **p < .01; ***p < .001; ****p < .0001.
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higher than recommended daily allowance across the lifespan (http://
nap.edu/11537). This high protein equivalent was dominated by amino
acids from medical foods; the proportion of intact protein relative to
BCAA-free protein equivalent decreased from ~25% during infancy to
~10% by adolescence (Fig. 3C).
Following the perinatal period, average plasma leucine
(218 ± 197 μmol/L, n = 6350) was typically within two standard
deviations above the reference mean until age 10 years, but 30–56%
higher (313 ± 301 μmol/L, n = 434; p < .0001) and more variable
(F = 2.33, p < .0001) thereafter. Parents checked an average of 64
(range 42–111) amino acid profiles during the first year of life.
Sampling frequency decreased as children got older and correlated in-
versely with annualized average plasma leucine (rs =−0.41, p = .007)
(Fig. 3D). Enrichment of medical food protein with SLC7A5 substrates
(phenylalanine, tryptophan, methionine, tyrosine, histidine, threonine)
[13] generally maintained their plasma concentrations above the
normal reference mean (Table 3) and preserved estimated average
brain influx within a broad but acceptable range (Fig. 3E). However,
despite 40–165% dietary enrichment relative to human milk [13],
average estimated cerebral uptake of certain key amino acids
(caption on next page)
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(tryptophan, methionine, histidine, glutamine) was nevertheless
23–34% lower than normal reference values (Table 3), reflecting strong
transport inhibition by elevated BCAAs (Fig. 1A), an inverse relation-
ship between leucine and several competing substrates (Fig. 2D), and
robust oxidation of surplus dietary amino acids [28].
Prospectively treated children had normal trajectories for weight,
length, and head circumference (Fig. S1). Outpatient laboratory studies
showed normal serum electrolytes, creatinine, glycohemoglobin, al-
bumin, total protein, hepatic transaminases, alkaline phosphatase, cell
counts, hemoglobin, red cell indices, total iron binding capacity, fer-
ritin, 25-hydroxyvitamin D, folate, vitamin B12, and carnitine profiles
(Table S3).
3.4. Liver transplantation and biomarkers
Between 2003 and 2018, 61 (33%) MSUD patients from our cohort
received an elective liver transplant at a median age of 9.7 (0.8–35.8)
years under a protocol jointly developed by clinical teams at CSC and
the UPMC Children's Hospital of Pittsburgh (Fig. 4A). Overall graft and
patient survival were 100%. There was no survival difference between
patients treated with liver transplant versus dietary therapy (χ2 = 1.39,
p = .239) and the transplant rate did not differ between Mennonite and
non-Mennonite individuals (χ2 = 5.8 p = .055). Thirteen (21%) liver
explants from MSUD donors were successfully ‘domino’ transplanted
into patients with other forms of liver disease [29]. Two transplanted
BCKDHA c.1312T > A homozygotes delivered healthy babies after
observing no special dietary restrictions during pregnancy.
Following liver transplantation, each plasma BCAA remained stable
at 1.5- to 2-times the reference mean in the face of intercurrent cata-
bolic stress and unrestricted natural protein ingestion (Fig. 4B, C,
Table 2). Alloisoleucine proved the most discriminating biomarker of in
vivo BCKD deficiency and had a linear correlation with plasma iso-
leucine in both classic (R2 = 0.50, p < .0001) and intermediate
(R2 = 0.67, p < .0001) MSUD patients on dietary therapy. Alloiso-
leucine was ≤5 μmol/L in 77% (n = 125) of post-transplant samples
(Fig. 4D). Among healthy control individuals, there was minimal var-
iation of plasma BCAA concentration ratios (Leu/Iso 1.81 ± 0.31; Val/
Leu 1.73 ± 0.21), reflecting natural stoichiometric regulation of α-
ketoacid oxidation by the intact BCKD complex. These ratios varied
across four orders of magnitude in patients with classic MSUD on
dietary therapy. Liver transplant almost completely restored stoichio-
metric regulation among the BCAAs despite their persistent elevation in
plasma (Fig. 4E, F).
Transplanted individuals from the present study represent 66% of
the total cohort of MSUD patients (n = 93) who received an elective
liver transplant at UPMC between 2003 and 2019. Among this larger
group, the most common indications for early post-transplant surgical
intervention were delayed wound closure (34%), chest tube drainage
(15%), and ventral hernia repair (11%) (Table S4). Post-transplant
exploratory laparotomies were performed for hepatic artery or graft
revision (5%), hepatic artery thrombosis (5%), partial small bowel
obstruction (4%), and intra-abdominal bleeding (3%). Major medical
complications were acute rejection (40%), Epstein-Barr virus (5%) and
cytomegalovirus (3%) disease, and immunosuppression-related lym-
phoproliferative disorder (3%).
3.5. Neuropsychiatric outcomes
Prospectively treated children with MSUD acquired major devel-
opmental milestones along time courses similar to their unaffected
siblings (Fig. 5). Among 82 MSUD patients who underwent neurocog-
nitive testing between 3.6 and 51.1 years of age, intelligence correlated
with birthdate (rs = 0.39, p = .0044) (Fig. 6A) and was on average
23% lower in a subgroup of 31 BCKDHA c.1312 T > A homozyogotes
(FSIQ 78 ± 18, range 40–113) as compared to their unaffected siblings
(FSIQ 100 ± 16, range 64–144). This latter difference did not vary
across subdomains and was most striking for 19 Mennonites born be-
fore 1989, who had an average FSIQ of 62 ± 17 (range 40–99),
12–60% below their age-matched siblings (Fig. 6B). Nine (42%) of
these individuals also had significant static motor disability. Using in-
complete retrospective data, neonatal encephalopathy was the only
other variable we could clearly correlate to FSIQ (Fig. 6C). Scores on
the SB-5 did not differ between Mennonite and non-Mennonite classic
MSUD patients born after 1988 (Fig. 6A).
The prevalence of affective illness (depression, anxiety, and panic
disorder) was alarmingly high among MSUD patients who completed
appropriate testing (n = 37) and also two-fold higher among their
siblings as compared to the general population (Fig. 6D). Liver trans-
plantation did not reverse pre-existing static encephalopathy, in-
tellectual disability, or mental illness (Fig. 6E), which appeared to drive
a strong linear correlation between birthdate and age of transplant
(R2 = 0.72, p < .0001) (Fig. 6F).
4. Discussion
4.1. Morbidity, mortality, and longitudinal metabolic control
Before 1989, one in three Mennonite children born with MSUD died
from complications of metabolic encephalopathy and the majority of
survivors were permanently disabled. Early efforts at CSC to integrate
metabolic services into primary care led to more rapid and affordable
amino acid testing, safer outpatient management of metabolic in-
stability, and locally accessible MSUD TPN [30]. As a result, 30-year
event-free survival increased from 63% to> 95%, hospitalization rates
decreased from 7 to just 0.25 hospital days per patient per year (Fig. 2A,
F) [31], and key outcome determinants became clear (Table 4).
Despite these advances in clinical care, classic MSUD remains a
morbid and potentially fatal disorder. The prescription diet maintains
average BCAA concentrations within acceptable limits (i.e. +3SDs
above the normal reference mean) but permits only ~10% of total
Fig. 3. Contemporary dietary management (n = 41, DOB 2005–2018): (A) Prescribed calories from formula (blue circles) aligned with predicted values until one
year of age; thereafter, calories from unquantified natural sources came to comprise ~30% of energy intake. Gray dashed line represents predicted calories based on
the doubly labeled water (DLW) method (http://nap.edu/11537). (B) Average weight-adjusted leucine tolerance (blue circles) correlated with weight gain (green
diamonds). (C) The proportion of ingested intact protein (blue circles) relative to BCAA-free protein equivalents (purple diamonds) decreased from ~25% during
infancy to ≤15% by adolescence. The total protein equivalent from intact plus BCAA-free sources was 25–50% higher than recommended daily allowance across the
lifespan. (D) Parents checked amino acid profiles most frequently during the first year of life (purple diamonds, dashed line; left ordinate axis). Sampling frequency
decreased thereafter, and correlated inversely (rs =−0.41, p = .007) with annualized average plasma leucine (blue circles, solid line; right ordinate axis). Values are
depicted as mean ± 1SD and gray shaded area represents the normal reference range for plasma leucine± 2SD (right ordinate axis). (E) Enrichment of medical food
with seven SLC7A5 substrates (purple diamonds: phenylalanine [Phe] tryptophan [Trp], methionine [Met], tyrosine [Tyr], histidine [His], threonine [Thr], and
glutamine [Gln]) maintained their plasma concentrations within 2SDs above the reference mean and partially defended estimated average brain influx. Gray shaded
area represents the normal z-score range of −2 to +2. (F) For each SLC7A5 substrate, we plotted average percentage difference as compared to the normal reference
mean (∆ Mean %) for its plasma concentration (abscissa) against its estimated brain influx (ordinate). In MSUD patients with chronically elevated BCAAs, the
competitive transport model predicts that the plasma concentration of any competing SLC7A5 substrate must be ~50% higher than the control reference mean
(purple dashed vertical line) to fully normalize its cerebral uptake (gray horizontal line). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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nutritional support from natural sources and does not prevent life-
threatening encephalopathic crises (Figs. 2B, C, and 3C). As with phe-
nylketonuria (PKU) [32,33], the frequency of amino acid monitoring
correlates with longitudinal metabolic control, both of which deterio-
rate with age (Fig. 3D) [34]. A minimum of 24 amino acid samples per
year (i.e. one every two weeks) is necessary to optimize control of
plasma leucine in older MSUD patients, none of whom actually adhere
to this schedule after 9 years of age.
4.2. Major determinants of neurocognitive outcome
Even with strict dietary control and frequent amino acid mon-
itoring, classic MSUD patients experience chronic amino acid and α-
ketoacid fluctuations that predispose to cognitive and psychiatric dis-
ability via overlapping mechanisms, including: (1) abiding neuro-
structural effects of severe and/or prolonged neonatal encephalopathy
(Fig. 6C) [12,35]; (2) chronically unbalanced amino acid transport
across the blood-brain barrier (Table 3, Figs. 1A, 3E, and F) [22,36]; (3)
cerebral deficiency of neurotransmitters such as glutamate, γ-amino-
butyric acid, dopamine, and serotonin [6,37,38] and (4) disturbances of
cerebral tricarboxylic acid flux and energy metabolism induced by αKIC
(Fig. 1B) [39]. In a previous study focused on a relatively uniform
subgroup of MSUD patients (N = 37) within a comparatively narrow
age range (5–35 years) [6], we correlated neuropsychiatric measures
with certain long-term biochemical and regional neurochemical pat-
terns (e.g., average lifetime plasma leucine and its ratio to valine and
tyrosine, as well as regional cerebral concentrations of glutamate, N-
acetylaspartate, and creatine).
The present MSUD cohort (n = 184) is comprised of more in-
dividuals over a much wider age range (0.1–52.9 years) with remote
medical records of variable quality and completeness; this limited our
analysis to only coarse-grained determinants of cognitive outcome such
as age and the presence or absence of neonatal encephalopathy (Fig. 6A
and C). The most severe disabilities were observed among patients born
before the advent of newborn screening, who commonly suffered
postnatal encephalopathy lasting weeks or months (Fig. 6B) [12], had
relatively infrequent amino acid monitoring [40], did not routinely
receive valine or isoleucine supplements early in life [6,30], ingested
formulas of variable composition quality and composition [13], and
were managed without the advantages of osmotic agents or customized
TPN (Table 1) [7,30]. These practice standards evolved in lockstep over
a span of five decades, making it challenging to discern the effect of any
one of them on outcome. Here, we can only confidently record the
‘aggregate’ benefit of improved clinical practices over time (Fig. 6B)
[31] and observe that children born with MSUD today in resource-
limited settings will face many of the same conditions and challenges
that prevailed in the U.S. fifty years ago [41–43].
4.3. Dietary treatment and outcome in the modern era
In 2005, we introduced new prescription medial foods designed to
counteract competitive inhibition of essential amino acid transport at
the blood-brain barrier and stabilize tissue concentrations of amino
acids depleted by αKIC [13]. These formulations have proven safe and
well-tolerated in 41 classic MSUD patients treated continuously from
birth (Fig. 3), supporting normal growth and milestone acquisition
while satisfying fundamental nutritional requirements through the
early developmental years (Fig. 5, Fig. S1, Table S3). Over longer
periods, enriching the diet with SLC7A5 substrates increases their
concentration in plasma but only partially safeguards their predicted
cerebral uptake (Fig. 3E and F, Table 3). This reflects strong transport
inhibition exerted by only modest elevations of leucine (Km= 29 μmol/
L) and isoleucine (Km= 56 μmol/L) (Figs. 1A and 3F) [22], suppression
of competing substrates in plasma by leucine and αKIC (Fig. 2D), and
the inherent challenge of overcoming oxidation pathways evolved to
maintain extracellular amino acid homeostasis in the face of broadTa
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Fig. 4. Liver transplantation and biomarkers (A) Sixty-one (33%) patients received a liver transplant at a median age of 9.7 (0.8–35.8) years and transplant rate did
not differ between Mennonites (solid blue line) and non-Mennonites (dashed purple line). (B) Following liver transplantation, weight-adjusted leucine intake
increased 5- to10-fold as plasma BCAAs remained stable at 1.5- to 2-times the reference mean in the face of intercurrent catabolic stress and unrestricted natural
protein ingestion (Control, control individuals; CL, classic MSUD on dietary therapy; INT, intermediate MSUD on dietary therapy; LT, classic MSUD patients following
liver transplantation). (C) Transplanted patients with classic MSUD (red diamonds) tolerate large protein boluses, shown here by the ability to oxidize a leucine load
of ~1500 mg within 45 min of ingesting a normal meal (gray squares: matched BCKDHA c.1312T > A heterozygous parents). In a non-transplanted patient, a
similar dietary load would acutely increase plasma leucine by 400–1000 μmol/L. (D) Plasma alloisoleucine had a strong linear correlation to isoleucine in patients
with classic (blue circles) and intermediate (purple triangles) MSUD on dietary therapy and was undetectable in 77% of blood samples collected after liver trans-
plantation (red diamonds). (E) Plasma concentration ratios among the BCAAs remain within narrow limits (Leu/Iso 1.81 ± 0.31; Val/Leu 1.73 ± 0.21) among
control individuals (gray squares) but vary across four orders of magnitude in patients with classic MSUD on dietary therapy (blue circles). (F) Liver transplantation
(red diamonds) partially restores regulation of BCAA ratios but at concentrations approximately 2-fold higher than control values (note log10 scales, panels E and F).
Asterisks represent statistically significant results of one-way ANOVA testing, with Tukey pairwise comparison p values of< 0.01(**),< 0.001 (***), or <
0.0001(****). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
K.A. Strauss, et al. Molecular Genetics and Metabolism xxx (xxxx) xxx–xxx
10
dietary variation [28,44].
Unfortunately, children detected by newborn screening and treated
prospectively using substrate-enriched medical foods nevertheless
scored 19 ± 15% lower than their siblings on intelligence scales and
were at least two-times more likely to develop mental illness (Fig. 5B
and D). These observations align with findings from other published
cohorts, which reveal increased risks of cognitive impairment, affective
disorders, executive dysfunction, emotional strain, unemployment, and
social dependence among MSUD patients managed in the modern era
[34,45]. Our findings also highlight the significant psychosocial mor-
bidity experienced by unaffected siblings (and presumably parents) of
MSUD patients (Fig. 6D). We could not attribute this to heterozygosity
for BCKDHA, BCKDHB, or DBT mutations. Rather, we believe it re-
presents the sustained psychological stress incurred by cohabitant fa-
mily members of any child afflicted with a chronic, serious, and/or life-
threatening illness, as has been observed repeatedly in other contexts
[46–48].
4.4. Liver transplantation and beyond
Many MSUD patients in developed countries ultimately choose or-
thotopic liver transplantation, which affords them an unrestricted diet
and protection from metabolic crises (Figs. 4A-C). However, a sig-
nificant number of transplanted patients experience surgical, infectious,
Fig. 5. Early Development. Early developmental milestone acquisition for 41 BCKDHA c.1312 T > A homozygotes, born 2005–2018 and treated from birth with a
single line of SLC7A5 substrate-enriched medical foods. MSUD patients represented by blue solid line were compared to their siblings who did not have MSUD (gray
dashed line). Milestones depicted: (A) independent sitting, (B) four-point crawl, (C) independent walking, (D) ascend stairs without assistance, (E) reciprocal verbal
communication with another individual, and (F) dress self without assistance. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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Fig. 6. Psychometric outcomes (A) Among all patients with classic MSUD, full-scale intelligence quotient (FSIQ) correlated with birthdate (rs = 0.39, p = .0044)
(purple diamonds, BCKDHA c.1312 T > A homozygotes born 1963–2004; blue circles, BCKDHA c.1312 T > A homozygotes born 2005–2018 and treated on
prospective dietary protocol; green diamonds, non-Mennonite classic MSUD) and (B) was on average 23% lower in patients as compared to their unaffected siblings
across subdomains (Mem, memory; VS, visual-spatial; QR, quantitative reasoning; Kno, fund of knowledge; FR, fluid reasoning, VIQ, verbal IQ; NVIQ, non-verbal IQ).
(C) Neonatal encephalopathy was the only other variable we were able to correlate with FSIQ in this large cohort. (D) The probability of affective illness (depression,
anxiety, and panic disorder) approached 100% by age 35 years in MSUD patients (blue solid line) and was two-fold higher among their siblings (purple dashed line)
as compared to the general population (gray dotted line). (E) Liver transplantation did not reverse pre-existing static encephalopathy, intellectual disability, or
mental illness, shown here as a non-significant average change (blue line, p = .165) in FSIQ among 20 MSUD patients who underwent neurocognitive testing before
(blue circles, FSIQ 78 ± 15) and ≥ 1 year after (red diamonds, FSIQ 81 ± 16) liver transplant. (F) There was a strong linear correlation between birthdate and age
of transplant. Asterisks represent statistically significant results of one-way ANOVA testing, with Tukey pairwise comparison p values of< 0.01 (**),< 0.001 (***),
or< 0.0001 (****). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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or malignant complications (Table S4) and their pre-existing neu-
ropsychiatric morbidities do not improve (Fig. 6E) [49]. The severity of
neurological disease preceding transplant is related to both the peri-
natal course and long-term metabolic control (Figs. 6A-C, Table 3) but
neurochemical disturbances persist after liver transplantation [6], in-
dicating that deficiency of BCKD in brain cells, which normally express
15–20% of total body enzyme activity [50], might impact cerebral
metabolism and function in ways independent of circulating BCAA and
BCKA concentrations.
Liver transplantation restores 9–13% of whole body BCKD activity
and represents a form of gene replacement therapy for MSUD. This sets
the stage for emerging DNA- and RNA-based treatment platforms. Intact
allogeneic liver tissue introduces just a fraction of potential BCKD ac-
tivity, most of which normally resides in human skeletal muscle
(54–66%) and brain (9–20%) [50]. Thus, one can expect an incremental
benefit of systemic vehicles such as adeno-associated viruses capable of
targeting transgene expression to the liver, muscle, and central nervous
system [9,51,52]. Newborn screening for MSUD, ubiquitous throughout
the United States and many developed nations, ensures that any new
disease-modifying therapy will exert its maximal clinical impact. One-
time molecular therapies might be especially valuable in resource-
limited settings, where therapeutic tools for managing MSUD are
woefully limited and outcomes remain poor [41–43].
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